Trial reportThe Journal of clinical endocrinology and metabolism2016
Influence of Postprandial Hyperglycemic Conditions on Arterial Stiffness in Patients With Type 2 Diabetes.
Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in The Journal of clinical endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Aortic Stiffness Measured by Carotid Femoral-Pulse Wave Velocity at Different Stages of Normal Glucose, Prediabetes, and Diabetes Mellitus: A Systematic Review and Meta-Analysis.Reviews in cardiovascular medicine · 2024Pooled it
- Trial
- Habitual isomaltulose intake reduces arterial stiffness associated with postprandial hyperglycemia in middle-aged and elderly people: a randomized controlled trial.Heart and vessels · 2024Trial
- Effects of Different Types of Carbohydrates on Arterial Stiffness: A Comparison of Isomaltulose and Sucrose.Nutrients · 2021Trial
- The Effect of Aerobic Exercise Training Frequency on Arterial Stiffness in a Hyperglycemic State in Middle-Aged and Elderly Females.Nutrients · 2021Trial
- Trial
- Insulin exposure mitigates the increase of arterial stiffness in patients with type 2 diabetes and albuminuria: an exploratory analysis.Acta diabetologica · 2019Trial
- Postprandial Effects of Breakfast Glycemic Index on Vascular Function among Young Healthy Adults: A Crossover Clinical Trial.Nutrients · 2017Trial
- Effects of a high-sugar mixed meal on cerebrovascular haemodynamics in young, healthy versus middle-aged adults with cardiometabolic risk factors.Experimental physiology · 2026Article
- Integration of chemical and physical inputs for monitoring metabolites and cardiac signals in diabetes.Nature biomedical engineering · 2026Article
- A Touch Enabled Hemodynamic and Metabolic Monitor.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Magnitude and determinants of isolated systolic hypertension among type 2 diabetes patients in selected referral hospitals in Amhara Region, Ethiopia.Scientific reports · 2025Article
- The Influence of Dietary Interventions on Arterial Stiffness in Overweight and Obese Subjects.Nutrients · 2023Review
- Dietary Risk Factors and Eating Behaviors in Peripheral Arterial Disease (PAD).International journal of molecular sciences · 2022Review
- Predictors of arterial stiffness in adolescents and adults with type 1 diabetes: a cross-sectional study.BMJ open diabetes research & care · 2022Article
- Assessment of Arterial Stiffness, Brachial Haemodynamics, and Central Haemodynamics in Diabetic Hypertensives: A Pulse Wave Analysis-Based Case-Control Study from an Urban Area of West India.Pulse (Basel, Switzerland) · 2021Article
- Postprandial variability of novel heart failure biomarkers in Fontan patients compared to healthy volunteers.International journal of cardiology. Congenital heart disease · 2021Article
- Maternal Glycemia During Pregnancy and Child Carotid Intima Media Thickness, Pulse Wave Velocity, and Augmentation Index.The Journal of clinical endocrinology and metabolism · 2020Article
- Effects of a short-term increase in physical activity on arterial stiffness during hyperglycemia.Journal of clinical biochemistry and nutrition · 2020Article
- Arterial stiffness during hyperglycemia in older adults with high physical activity vs low physical activity.Journal of clinical biochemistry and nutrition · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 2 countries.
Daniel GordinFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Markku SaraheimoFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Jaana TuomikangasFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Aino Soro-PaavonenFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Carol ForsblomFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Karri PaavonenFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Birgit Steckel-HamannFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Francois VandenhendeFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Loizos NicolaouFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Imre PavoFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Veikko KoivistoFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Per-Henrik GroopFolkhälsan Institute of Genetics (D.G., M.S., J.T., A.S.-P., C.F., K.P., P.-H.G.), Folkhälsan Research Center, Biomedicum Helsinki, FI-00014 Helsinki, Finland; Abdominal Center Nephrology FI-00290 (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), University of Helsinki and Helsinki University Hospital, and Research Program Unit (D.G., M.S., J.T., A.S.-P., C.F., P.-H.G.), Department of Diabetes and Obesity, University of Helsinki FI-00014, and Division of Cardiology (K.P.), Department of Medicine, Helsinki University Central Hospital, FI-00290 Helsinki, Finland; Eli Lilly Export SA (B.S.-H.), Vernier, 1214 Geneva, Switzerland; ClinBAY (F.V., L.N.), 1470 Genappe, Belgium; Eli Lilly (I.P.), A-1030 Vienna, Austria; Eli Lilly (V.K.), 00330 Helsinki, Finland; and Baker IDI and Diabetes Institute (P.-H.G.), Melbourne, 3004 Victoria, Australia.
Institute of Genetics · HU
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPatients with type 2 diabetes (T2D) are at an increased risk of cardiovascular disease.
objectiveThe objective of the study was to determine whether postprandial hyperglycemia affects arterial function in T2D.
designA single-center, open-label study of three groups of men were studied: 1) T2D patients with albuminuria (n = 22), 2) T2D patients without albuminuria (n = 24), and 3) nondiabetic controls (n = 25). Patients were randomized to a two-period crossover study schedule, ingesting breakfast, with or without insulin lispro (to induce low or high postprandial glycemia).
main outcome measuresArterial stiffness was assessed by calculating pulse wave velocity (PWV) and augmentation index using applanation tonometry, and endothelial dysfunction was assessed using peripheral arterial tonometry, 30 minutes before breakfast and up to 240 minutes after breakfast.
resultsAt baseline, arterial stiffness was increased in patients. When adjusted for age and body mass index, in a combined group of patients with and without albuminuria, brachial PWV was higher during low (P = .032) and high (P = .038) postprandial glycemia vs controls. These differences were driven by the albuminuria group vs controls during low (P = .014) and high (P = .018) postprandial glycemia. No differences were observed in aortic PWV, augmentation index, or peripheral arterial tonometry ratio between patients and controls. Endothelin-1 and IL-6 were higher, and superoxide dismutase was lower, during postprandial hyperglycemia in T2D patients vs controls.
conclusionsIn patients with T2D and albuminuria, brachial PWV was higher under postprandial hyperglycemic conditions, relative to controls. These data suggest that hyperglycemia induces an increase in stiffness of intermediate-sized arteries. We found no changes in other parts of the arterial bed.
Indexed as
AgedBlood Flow VelocityBlood GlucoseCross-Over StudiesDiabetes Mellitus, Type 2Diabetic AngiopathiesHumansHyperglycemiaInsulinMaleMiddle AgedPostprandial PeriodPulse Wave AnalysisRadial ArteryVascular StiffnessBlood GlucoseInsulin
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.